Insulin Delivery Devices Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The report covers Global Insulin Delivery Devices Market Share and it is segmented by Type (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, Jet Injectors), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America). The market values are provided in terms of (USD million) for the above segments.

Home Market Analysis Healthcare Research Device Drug Combination Research Diagnostics and Therapeutics Research Diabetes Care Research Insulin Delivery System Industry

Insulin Delivery Devices Market Size

Insulin Delivery Devices Market Summary
Study Period 2019 - 2029
Market Size (2024) USD 39.57 Billion
Market Size (2029) USD 47.17 Billion
CAGR (2024 - 2029) 3.57 %
Fastest Growing Market North America
Largest Market Asia Pacific

Major Players

Insulin Delivery Devices Market Major Players

*Disclaimer: Major Players sorted in no particular order
setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Insulin Delivery Devices Market Analysis

The Insulin Delivery Devices Market size is estimated at USD 39.57 billion in 2024, and is expected to reach USD 47.17 billion by 2029, growing at a CAGR of 3.57% during the forecast period (2024-2029).

The COVID-19 pandemic substantially impacted the insulin delivery devices market. Type-1 diabetes patients are impacted more during COVID-19. People with diabetes have a weak immune system; hence, with COVID-19, the immune system gets weaker fast. People with diabetes may have more chances of serious complications than normal people. The manufacturers of insulin delivery devices have taken care during COVID-19 to deliver insulin delivery devices to diabetes patients with the help of local governments. NovoNordisk stated on their website that 'Since the start of COVID-19, our commitment to patients, our employees, and the communities where we operate has remained unchanged, we continue to supply our medicines and devices to people living with diabetes and other serious chronic diseases, safeguard the health of our employees, and take actions to support doctors and nurses as they work to defeat COVID-19.' Doctors globally suggest diabetes patients check their diabetes levels more often to be careful. The intake of medicine has increased, leading to an increased usage of insulin delivery devices.

According to International Diabetes Federation (IDF), the adult diabetes population in 2021 was approximately 537 million, and this number is expected to increase by 643 million in 2030. Approximately 10% of the total diabetes population has Type-1 diabetes, and of this 10% of people, only 80-90% use insulin delivery devices; however, the usage of insulin is rising from time to time, and even Type-2 diabetes patients are using the insulin delivery devices during COVID-19.

Technological advancements in insulin delivery devices have increased over time for safer and more accurate insulin administration. Therefore, owing to the factors mentioned above, the studied market is anticipated to witness growth over the analysis period.

Insulin Delivery Devices Market Trends

This section covers the major market trends shaping the Insulin Delivery Devices Market according to our research experts:

Insulin Pump is Expected to Witness Growth Over the Forecast Period

An insulin pump is a device that delivers insulin continuously or, whenever required, automatically. The pump mimics the human pancreas. The insulin infusion pump works as an alternative to the traditional system of daily injections or an insulin pen.

Insulin pumps held 8% of the market share in the insulin delivery devices market in 2021, and it is expected to grow with a CAGR of 7% in the market, which is higher than other insulin delivery devices because of the increasing technological advancement and its preference over other traditional methods due to continuous insulin administration.

Insulin pump therapy is a well-established insulin administration method for type 1 diabetes (T1DM). Pumps are a validated, time-tested therapeutic option in T1DM at all ages, enabling near-physiological insulin delivery in situations where the pancreas does not produce insulin. There are even pump models with remote controls enabling parents of young children to either suspend or bolus insulin from a distance when the child is playing or eating.

The insulin infusion pumps reduce the large swings in blood glucose level, induce less pain, and deliver more accurately when compared to injections. These advantages of insulin pumps over the traditional delivery system are expected to boost the market.

The market also benefits massively from the constant rise in the number of vendors, R&D activities, technological advancements in products, and the easy availability of advanced products globally. Moreover, favorable reimbursement scenarios in developed nations and a constant rise in awareness programs across developing economies are also working in favor of the market.

Insulin Delivery Devices Market : Revenue in USD million, Insulin pump, (2022 - 2027)

North America is Expected to Dominate the Insulin Delivery Devices Market

North America is expected to dominate the market owing to factors such as the easy availability of insulin delivery devices and high awareness among consumers.

The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure in the United States indicate the increasing usage of diabetes care products. In the United States, according to the Academy of Managed Care Pharmacy, insulin pumps cost between USD 4,500 and USD 6,500 for individuals without insurance. The price varies depending upon the pump's features, brand, and size. For example, the Accu-Chek Spirit Insulin Pump costs about USD 4,600 and includes a few features, such as software that allows readings to be downloaded to a personal digital assistant (PDA). The Minimed Paradigm 522 is more expensive, retailing at about USD 5,200, and includes more features, like continuous glucose monitoring. Some insurance plans will cover the cost of the pump. Patients with insurance may expect typical copay and coinsurance rates ranging from USD 5 to half of the pump's total cost. Despite prices, diabetes patients in the United States use insulin delivery devices more often.

In 2021, the United States recorded the highest market share, with more than 20% in the insulin delivery devices market, followed by Japan and India. The rising diabetic population and the accessibility of technologically advanced devices contribute to the high market growth in the United States. According to Mordor Intelligence statistics, in 2021, around 37 million people in the United States had diabetes; among them, approximately 26.35 million patients were diagnosed, whereas about 10.1 million patients remained undiagnosed. Thus, the large patient base suffering from diabetes and its growing prevalence is expected to boost the growth in this region.

Therefore, owing to the factors described above, the growth of the market studied is anticipated in the North American Region.

Insulin Delivery Devices Market : Diabetes Population in million, United States, (2016 - 2021)

Insulin Delivery Devices Industry Overview

The insulin delivery devices market is consolidated due to only a few major companies operating globally and regionally. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known, including Novo Nordisk, Sanofi, Eli Lily and Company, Medtronic, Insulet, Ypsomped, Becton, Dickinson and Company, among others.

Insulin Delivery Devices Market Leaders

  1. Novo Nordisk

  2. Medtronic

  3. Sanofi

  4. Ypsomed

  5. Eli Lilly and Company

*Disclaimer: Major Players sorted in no particular order

Insulin Delivery Devices Market Concentration
Need More Details on Market Players and Competitors?
Download PDF

Insulin Delivery Devices Market News

  • In March 2022, Novo Nordisk announced that two smart connected insulin pens, NovoPen 6 and NovoPen Echo Plus, were available on prescription for people with diabetes treated with Novo Nordisk insulin in the United Kingdom.
  • In January 2022, Boston-based Insulet Corp. announced that the FDA (Food and Drug Administration) cleared the new Omnipod 5 system, marking the company's entry into the automated insulin delivery (AID) universe.

Insulin Delivery Devices Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

    3. 4.3 Market Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. Market Segmentation

    1. 5.1 By Management Devices

      1. 5.1.1 Insulin Pump

        1. 5.1.1.1 Insulin Pump Devices (Value and Volume, 2016 - 2027)

        2. 5.1.1.2 Insulin Pump Reservoirs (Value and Volume, 2016 - 2027)

        3. 5.1.1.3 Infusion Sets (Value and Volume, 2016 - 2027)

      2. 5.1.2 Insulin Syringes (Value and Volume, 2016 - 2027)

      3. 5.1.3 Cartridges in reusable pens (Value and Volume, 2016 - 2027)

      4. 5.1.4 Disposable Pens (Value and Volume, 2016 - 2027)

      5. 5.1.5 Jet Injectors (Value and Volume, 2016 - 2027)

    2. 5.2 Geography

      1. 5.2.1 North America

        1. 5.2.1.1 United States (Value and Volume, 2016 - 2027)

          1. 5.2.1.1.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)

        2. 5.2.1.2 Canada (Value and Volume, 2016 - 2027)

          1. 5.2.1.2.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)

        3. 5.2.1.3 Rest of North America (Value and Volume, 2016 - 2027)

          1. 5.2.1.3.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)

      2. 5.2.2 Europe

        1. 5.2.2.1 France (Value and Volume, 2016 - 2027)

          1. 5.2.2.1.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)

        2. 5.2.2.2 Germany (Value and Volume, 2016 - 2027)

          1. 5.2.2.2.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)

        3. 5.2.2.3 Italy (Value and Volume, 2016 - 2027)

          1. 5.2.2.3.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)

        4. 5.2.2.4 Spain (Value and Volume, 2016 - 2027)

          1. 5.2.2.4.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)

        5. 5.2.2.5 United Kingdom (Value and Volume, 2016 - 2027)

          1. 5.2.2.5.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)

        6. 5.2.2.6 Russia (Value and Volume, 2016 - 2027)

          1. 5.2.2.6.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)

        7. 5.2.2.7 Rest of Europe (Value and Volume, 2016 - 2027)

          1. 5.2.2.7.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)

      3. 5.2.3 Latin America

        1. 5.2.3.1 Mexico (Value and Volume, 2016 - 2027)

          1. 5.2.3.1.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)

        2. 5.2.3.2 Brazil (Value and Volume, 2016 - 2027)

          1. 5.2.3.2.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)

        3. 5.2.3.3 Rest of Latin America (Value and Volume, 2016 - 2027)

          1. 5.2.3.3.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)

      4. 5.2.4 Asia-Pacific

        1. 5.2.4.1 Japan (Value and Volume, 2016 - 2027)

          1. 5.2.4.1.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)

        2. 5.2.4.2 South Korea (Value and Volume, 2016 - 2027)

          1. 5.2.4.2.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)

        3. 5.2.4.3 China (Value and Volume, 2016 - 2027)

          1. 5.2.4.3.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)

        4. 5.2.4.4 India (Value and Volume, 2016 - 2027)

          1. 5.2.4.4.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)

        5. 5.2.4.5 Australia (Value and Volume, 2016 - 2027)

          1. 5.2.4.5.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)

        6. 5.2.4.6 Vietnam (Value and Volume, 2016 - 2027)

          1. 5.2.4.6.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)

        7. 5.2.4.7 Malaysia (Value and Volume, 2016 - 2027)

          1. 5.2.4.7.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)

        8. 5.2.4.8 Indonesia (Value and Volume, 2016 - 2027)

          1. 5.2.4.8.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)

        9. 5.2.4.9 Philippines (Value and Volume, 2016 - 2027)

          1. 5.2.4.9.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)

        10. 5.2.4.10 Thailand (Value and Volume, 2016 - 2027)

          1. 5.2.4.10.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)

        11. 5.2.4.11 Rest of Asia-Pacific (Value and Volume, 2016 - 2027)

          1. 5.2.4.11.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)

      5. 5.2.5 Middle-East and Africa

        1. 5.2.5.1 Saudi Arabia (Value and Volume, 2016 - 2027)

          1. 5.2.5.1.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)

        2. 5.2.5.2 Iran (Value and Volume, 2016 - 2027)

          1. 5.2.5.2.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)

        3. 5.2.5.3 Egypt (Value and Volume, 2016 - 2027)

          1. 5.2.5.3.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)

        4. 5.2.5.4 Oman (Value and Volume, 2016 - 2027)

          1. 5.2.5.4.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)

        5. 5.2.5.5 South Africa (Value and Volume, 2016 - 2027)

          1. 5.2.5.5.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)

        6. 5.2.5.6 Rest of Middle-East and Africa (Value and Volume, 2016 - 2027)

          1. 5.2.5.6.1 By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)

  6. 6. MARKET INDICATORS

    1. 6.1 Type-1 Diabetes population (2016 - 2027)

    2. 6.2 Type-2 Diabetes population (2016 - 2027)

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 Company profiles

      1. 7.1.1 Novo Nordisk AS

      2. 7.1.2 Sanofi SA

      3. 7.1.3 Eli Lilly and Company

      4. 7.1.4 Medtronic PLC

      5. 7.1.5 Insulet corporation

      6. 7.1.6 Ypsomed

      7. 7.1.7 Becton, Dickinson and Company

    3. 7.2 Company Share Analysis

      1. 7.2.1 Novo Nordisk AS

      2. 7.2.2 Sanofi SA

      3. 7.2.3 Eli Lilly and Company

      4. 7.2.4 Others

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Insulin Delivery Devices Industry Segmentation

The insulin delivery devices market is expected to register a CAGR greater than 3% over the forecast period. The insulin delivery devices market is segmented by type (insulin pumps, insulin syringes, cartridges in reusable pens, disposable pens, jet injectors) and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and Latin America). The report offers the value (in USD million) for the above segments. The report also covers the estimated market sizes and trends for 25 countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Management Devices
Insulin Pump
Insulin Pump Devices (Value and Volume, 2016 - 2027)
Insulin Pump Reservoirs (Value and Volume, 2016 - 2027)
Infusion Sets (Value and Volume, 2016 - 2027)
Insulin Syringes (Value and Volume, 2016 - 2027)
Cartridges in reusable pens (Value and Volume, 2016 - 2027)
Disposable Pens (Value and Volume, 2016 - 2027)
Jet Injectors (Value and Volume, 2016 - 2027)
Geography
North America
United States (Value and Volume, 2016 - 2027)
By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
Canada (Value and Volume, 2016 - 2027)
By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
Rest of North America (Value and Volume, 2016 - 2027)
By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
Europe
France (Value and Volume, 2016 - 2027)
By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
Germany (Value and Volume, 2016 - 2027)
By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
Italy (Value and Volume, 2016 - 2027)
By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
Spain (Value and Volume, 2016 - 2027)
By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
United Kingdom (Value and Volume, 2016 - 2027)
By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
Russia (Value and Volume, 2016 - 2027)
By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
Rest of Europe (Value and Volume, 2016 - 2027)
By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
Latin America
Mexico (Value and Volume, 2016 - 2027)
By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
Brazil (Value and Volume, 2016 - 2027)
By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
Rest of Latin America (Value and Volume, 2016 - 2027)
By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
Asia-Pacific
Japan (Value and Volume, 2016 - 2027)
By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
South Korea (Value and Volume, 2016 - 2027)
By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
China (Value and Volume, 2016 - 2027)
By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
India (Value and Volume, 2016 - 2027)
By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
Australia (Value and Volume, 2016 - 2027)
By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
Vietnam (Value and Volume, 2016 - 2027)
By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
Malaysia (Value and Volume, 2016 - 2027)
By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
Indonesia (Value and Volume, 2016 - 2027)
By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
Philippines (Value and Volume, 2016 - 2027)
By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
Thailand (Value and Volume, 2016 - 2027)
By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
Rest of Asia-Pacific (Value and Volume, 2016 - 2027)
By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
Middle-East and Africa
Saudi Arabia (Value and Volume, 2016 - 2027)
By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
Iran (Value and Volume, 2016 - 2027)
By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
Egypt (Value and Volume, 2016 - 2027)
By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
Oman (Value and Volume, 2016 - 2027)
By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
South Africa (Value and Volume, 2016 - 2027)
By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
Rest of Middle-East and Africa (Value and Volume, 2016 - 2027)
By Devices (Insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors)
Need A Different Region Or Segment?
Customize Now

Insulin Delivery Devices Market Research FAQs

The Insulin Delivery Devices Market size is expected to reach USD 39.57 billion in 2024 and grow at a CAGR of 3.57% to reach USD 47.17 billion by 2029.

In 2024, the Insulin Delivery Devices Market size is expected to reach USD 39.57 billion.

Novo Nordisk, Medtronic, Sanofi, Ypsomed and Eli Lilly and Company are the major companies operating in the Insulin Delivery Devices Market.

North America is estimated to grow at the highest CAGR over the forecast period (2024-2029).

In 2024, the Asia Pacific accounts for the largest market share in Insulin Delivery Devices Market.

In 2023, the Insulin Delivery Devices Market size was estimated at USD 38.21 billion. The report covers the Insulin Delivery Devices Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Insulin Delivery Devices Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.

Insulin Pumps Industry Report

Statistics for the 2024 Insulin Pumps market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Insulin Pumps analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.

Insulin Pumps Market Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!

Insulin Delivery Devices Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)